BIOIO, LLC
Saint Louis, MO · Biotech · Private
Novel small-molecule insulin-sensitizing compounds (MSDC-5514 and MSDC-5445) targeting PLD1 signaling for NASH treatment
- Grants
- $2.9M
- 5 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20192020202120222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Novel insulin-sensitizing NASH/diabetes drugs. | $223,817 | |
| Federal grant | Department of Health and Human Services · Phase I · Drug target identification using CRISPRi/a screening | $224,455 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel insulin-sensitizing NASH/diabetes drugs. | $1,492,578 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel insulin-sensitizing NASH/diabetes drugs. | $497,526 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel insulin-sensitizing NASH/diabetes drugs. | $497,526 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2534 | A2 THERAPEUTICS, INC. | — | — |
| 2535 | Deverra Therapeutics | — | $2.5M |
| 2536 | ELIAS Animal Health, LLC | — | $2.4M |
| 2537 | BIOIO, LLC | — | — |
| 2538 | EIKONIZO THERAPEUTICS, INC. | — | $2.4M |
| 2539 | Topos Bio, Inc. | — | $9.0M |
| 2540 | Addition Therapeutics | — | $28M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.